Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study - Concepedia

Concepedia

Publication | Open Access

Lanadelumab in Patients 2 to Less Than 12 Years Old With Hereditary Angioedema: Results From the Phase 3 SPRING Study

DOI Full Paper Access

23

Citations

20

References

2023

Year

Marcus Maurer, William R. Lumry, H. Henry Li, Emel Aygören‐Pürsün, Paula J. Busse, Joshua Jacobs, Christina Nurse, Mariam A. Ahmed, Maureen Watt, Ming Yu,

The Journal of Allergy and Clinical Immunology In Practice

Abstract

Findings support safety, efficacy, and improved HRQoL with lanadelumab 150 mg Q2W and Q4W regimens for the prevention of HAE attacks in patients aged 2 to less than 12 years.

References

	Year	Citations

Page 1